OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Monday, August 20, 2012

Body composition changes in females treated for breast cancer: a review of the evidence




Body composition changes in females treated for breast cancer: a review of the evidence

Abstract  
Body composition changes cannot be precisely captured using body weight or body mass index measures. Therefore, the primary
purpose of this review was to characterize the patterns of body composition change in females treated for breast cancer including
only studies that utilize imaging technologies to quantify adipose tissue and lean body mass (LBM). We reviewed PubMed for
studies published between 1971 and 2012 involving females diagnosed with breast cancer where computed axial tomography , dual-energy
X-ray absorptiometry, or magnetic resonance imaging were employed for body composition assessment. Of the initial 440 studies,
106 papers were evaluated and 36 papers met all eligibility criteria (15 observational and 21 intervention trials). Results
of these studies revealed that body weight did not consistently increase. Importantly, studies also showed that body weight
did not accurately depict changes in lean or adipose tissues. Further findings included that sarcopenic obesity as a consequence
of breast cancer treatment was not definitive, as menopausal status may be a substantial moderator of body composition. Overall,
the behavioral interventions did not exhibit consistent or profound effects on body composition outcomes; approximately half
showed favorable influence on adiposity while the effects on LBM were not apparent. The use of tamoxifen had a clear negative
impact on body composition. The majority of studies were conducted in predominantly white survivors, highlighting the need
for trials in minority populations. Collectively, these studies were limited by age, race, and/or menopause status matched
control groups, overall size, and statistical power. Very few studies simultaneously collected diet and exercise data—two
potential factors that impact body composition. Future breast cancer trials should prioritize precise body composition methodologies
to elucidate how these changes impact recurrence, prognosis, and mortality, and to provide clinicians with appropriate advice
regarding lifestyle recommendations in this growing sector of the population.

The Canadian Medical Association: From Profit to Equity | Open Medicine



Surgeries to Be Broadcast Live on the Internet



http://www.newswise.com/articles/view/592772/?sc=rsla&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+NewswiseLatestNews+%28Newswise%3A+Latest+News%29&utm_content=Google+Reader

Forbes article: on fixing the healthcare system + other articles



http://www.forbes.com/sites/stevedenning/2012/08/20/another-non-solution-for-us-health-care-the-competition-tooth-fairy/

Anti-cancer regimens with multiple modes of action increase treatment effectiveness



http://www.news-medical.net/post.aspx?id=400cfe26-beed-4a99-8e4b-cdde9b6aefd1

More trial, less error - An effort to improve scientific studies



http://reut.rs/ShFG6y

Chemo-Resistant Ovarian Cancer | Medical News and Health Information



http://www.ivanhoe.com/channels/p_channelstory.cfm?storyid=29895

Trials | Abstract | Drug safety assessment in clinical trials: methodological challenges and opportunities



Open AccessReview

Drug safety assessment in clinical trials: methodological challenges and opportunities

Sonal Singh and Yoon K Loke

For all author emails, please log on.

Trials 2012, 13:138 doi:10.1186/1745-6215-13-138

Published: 20 August 2012

Abstract (provisional)

Randomized controlled trials are the principal means of establishing the efficacy of drugs. However pre-marketing trials are limited in size and duration and exclude high-risk populations. They have limited statistical power to detect rare but potentially serious adverse events in real-world patients. We summarize the principal methodological challenges in the reporting, analysis and interpretation of safety data in clinical trials using recent examples from systematic reviews. The principle challenges include the lack of an evidentiary gold standard, the limited statistical power of randomized controlled trials and resulting type 2 error, the lack of adequate ascertainment of adverse events and limited generalizability of safety trials that exclude high risk patients. We discuss potential solutions to these challenges. Evaluation of drug safety requires careful examination of data from heterogeneous sources. Meta-analyses of drug safety should include appropriate statistical methods and assess the optimal information size to avoid type 2 errors. They should evaluate outcome reporting biases and missing data to ensure reliable and accurate interpretation of findings. Regulatory and academic partnerships should be fostered to provide an independent and transparent evaluation of drug safety.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.




Sunday, August 19, 2012

Current Opinion in Oncology - Robotic surgery in gynecologic oncology



http://mobile.journals.lww.com/co-oncology/_layouts/oaks.journals.mobile/abstractviewer.aspx?year=2012&issue=09000&article=00013

A Nonsynonymous Polymorphism inIRS1 Modifies Risk of Developing Breast and Ovarian Cancers inBRCA1 and Ovarian Cancer



A Nonsynonymous Polymorphism inIRS1 Modifies Risk of Developing Breast and Ovarian Cancers inBRCA1 and Ovarian Cancer inBRCA2 Mutation Carriers

 Authors

Abstract

Background: We previously reported significant associations between genetic variants in insulin receptor substrate 1 (IRS1) and breast cancer risk in women carrying BRCA1 mutations. The objectives of this study were to investigate whether the IRS1 variants modified ovarian cancer risk and were associated with breast cancer risk in a larger cohort of BRCA1 and BRCA2mutation carriers......



CEBP: « PreviousNext Article » TOC Use of Fertility Drugs and Risk of Ovarian Cancer: Results from a U.S.-Based Case–Control Study



http://m.cebp.aacrjournals.org/content/21/8/1282.short

CAPR: Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening open access version



http://m.cancerpreventionresearch.aacrjournals.org/content/5/8/1015.full

.....impact of ovarian cancer screening




Abstract

Ongoing ovarian cancer screening trials are investigating the efficacy of a two-step screening strategy using currently available blood and imaging tests [CA125 and transvaginal sonography (TVS)]. Concurrently, efforts to develop new biomarkers and imaging tests seek to improve screening performance beyond its current limits. This study estimates the mortality reduction, years of life saved, and cost-effectiveness achievable by annual multimodal screening using increasing CA125 to select women for TVS, and predicts improvements achievable by replacing currently available screening tests with hypothetical counterparts with better performance characteristics. An existing stochastic microsimulation model is refined and used to screen a virtual cohort of 1 million women from ages 45 to 85 years. Each woman is assigned a detailed disease course and screening results timeline. The preclinical behavior of CA125 and TVS is simulated using empirical data derived from clinical trials. Simulations in which the disease incidence and performance characteristics of the screening tests are independently varied are conducted to evaluate the impact of these factors on overall screening performance and costs. Our results show that when applied to women at average risk, annual screening using increasing CA125 to select women for TVS achieves modest mortality reduction (∼13%) and meets currently accepted cost-effectiveness guidelines. Screening outcomes are relatively insensitive to second-line test performance and costs. Identification of a first-line test that does substantially better than CA125 and has similar costs is required for screening to reduce ovarian mortality by at least 25% and be reasonably cost-effective.Cancer Prev Res; 5(8); 1015–24. ©2012 AACR.




Sent from my iPhone

Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening



http://m.cancerpreventionresearch.aacrjournals.org/content/5/8/1015.short

ScienceDirect.com - Gynecologic Oncology Case Reports - Management of a skin metastasis in a patient with advanced ovarian cancer



Management of a skin metastasis in a patient with advanced ovarian cancer




Sent from my iPhone

Saturday, August 18, 2012

Radon gas deadlier than thought: Radioactive substance causes 16% of lung cancer cases, Health Canada says | media



http://news.nationalpost.com/2012/08/17/radon-gas-deadlier-than-thought-radioactive-substance-causes-16-of-lung-cancer-cases-health-canada-says/


Sent from my iPhone

Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes - McBride - 2012 - The Journal of Pathology - Wiley Online Library




Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes

  1. David J McBride1,‡,*
  2. Dariush Etemadmoghadam2,3,‡,*
  3. Susanna L Cooke1,4,‡,*
  4. Kathryn Alsop2,5
  5. Joshy George2,5
  6. Adam Butler1
  7. Juok Cho1,
  8. Danushka Galappaththige1
  9. Chris Greenman1
  10. Karen D Howarth6
  11. King W Lau1
  12. Charlotte K Ng4
  13. Keiran Raine1
  14. Jon Teague1
  15. David C Wedge1
  16. Australian Ovarian Cancer Study Group2
  17. Xavier Caubit7
  18. Michael R Stratton1
  19. James D Brenton4
  20. Peter J Campbell1
  21. P Andrew Futreal1,§
  22. David DL Bowtell2,5,8,§,*

Article first published online: 6 JUN 2012

The Journal of Pathology

The Journal of Pathology

Volume 227Issue 4pages 446–455August 2012



Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT)



Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type (OSCCHT)




[Intraoperative frozen sections in diseases of the female genital tract.]



[Intraoperative frozen sections in diseases of the female genital tract.]




Sent from my iPhone

Friday, August 17, 2012

ScienceDirect.com - European Journal of Obstetrics & Gynecology and Reproductive Biology - Ethical guidelines and the prevention of abuse in healthcare



http://www.sciencedirect.com/science/article/pii/S0301211512003375

Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al. - Decision | American Civil Liberties Union (brca patent issue)



http://www.aclu.org/womens-rights/association-molecular-pathology-et-al-v-us-patent-and-trademark-office-et-al-decision

PHG Foundation | The challenges posed by direct-to-consumer genetic tests



Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer - Cochrane Review



Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.

A

BACKGROUND: Epithelial ovarian cancer presents at an advanced stage in the majority of women. These women require surgery and chemotherapy for optimal treatment. Conventional treatment is to perform surgery first and then give chemotherapy. However, it is not yet clear whether there are any advantages to using chemotherapy before surgery.
OBJECTIVES: To assess whether there is an advantage to treating women with advanced epithelial ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery.
SEARCH METHODS: For the original review we searched, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2006), MEDLINE (Silver Platter, from 1966 to 1 Sept 2006), EMBASE via Ovid (from 1980 to 1 Sept 2006), CANCERLIT (from 1966 to 1 Sept 2006), PDQ (search for open and closed trials) and MetaRegister (most current search Sept 2006). For this update randomised controlled trials (RCTs) were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 3, 2011) and the Cochrane Gynaecological Cancer Specialised Register (2011), MEDLINE (August week 1, 2011), EMBASE (to week 31, 2011), PDQ (search for open and closed trials) and MetaRegister (August 2011).
SELECTION CRITERIA: RCTs of women with advanced epithelial ovarian cancer (Federation of International Gynaecologists and Obstetricians (FIGO) stage III/IV) who were randomly allocated to treatment groups that compared platinum-based chemotherapy before cytoreductive surgery with platinum-based chemotherapy following cytoreductive surgery.
DATA COLLECTION AND ANALYSIS: Data were extracted by two review authors independently, and the quality of included trials was assessed by two review authors independently.
MAIN RESULTS: One high-quality RCT met the inclusion criteria. This multicentre trial randomised 718 women with stage IIIc/IV ovarian cancer to NACT followed by interval debulking surgery (IDS) or primary debulking surgery (PDS) followed by chemotherapy. There were no significant differences between the study groups with regard to overall survival (OS) (670 women; HR 0.98; 95% CI 0.82 to 1.18) or progression-free survival (PFS) (670 women; HR 1.01; 95% CI 0.86 to 1.17).Significant differences occurred between the NACT and PDS groups with regard to some surgically related serious adverse effects (SAE grade 3/4) including haemorrhage (12 in NACT group vs 23 in PDS group; RR 0.50; 95% CI 0.25 to 0.99), venous thromboembolism (none in NACT group vs eight in PDS group; RR 0.06; 95% CI 0 to 0.98) and infection (five in NACT group vs 25 in PDS group; RR 0.19; 95% CI 0.07 to 0.50). Quality of life (QoL) was reported to be similar for the NACT and PDS groups.Three ongoing RCTs were also identified.
AUTHORS' CONCLUSIONS: We consider the use of NACT in women with stage IIIc/IV ovarian cancer to be a reasonable alternative to PDS, particularly in bulky disease. With regard to selecting who will benefit from NACT, treatment should be tailored to the patient and should take into account resectability, age, histology, stage and performance status. These results cannot be generalised to women with stage IIIa and IIIb ovarian cancer; in these women, PDS is the standard. We await the results of three ongoing trials, which may change these conclusions.



Issue 8, 2012 of The Cochrane Library is now available | The Cochrane Collaboration



Issue 8, 2012 of The Cochrane Library is now available

Issue 8, 2012 of The Cochrane Library is now available! New and updated reviews available on interventions for health-related quality of life for cancer survivors, weight loss and maintenance, and high blood pressure.

Contributor's Information
Contributor's name: 
Cochrane Web Team


Revisiting the complexity of the ovaria - PubMed Mobile




Revisiting the complexity of the ovarian cancer microenvironment-clinical implications for treatment strategies.

Authors

Musrap N, Diamandis EP.

Journal

Mol Cancer Res. 2012 Aug 15. [Epub ahead of print]

Affiliation

University of Toronto.

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death among gynaecological malignancies in North American women. Given that EOC encompasses a broad class of tumors consisting of a variety of different histological and molecular subtypes, which generates genetically and etiologically distinct tumors, several challenges arise during treatment of patients with this disease. Overlaying this complexity is the contribution of supporting cells, particularly stromal components such as fibroblasts and immune infiltrates that collectively create a microenvironment that promotes and enhances cancer progression. A notable example is the induction of angiogenesis, which occurs through the secretion of pro-angiogenic factors by both tumor and tumor-associated cells. The recent development of angiogenic inhibitors targeting tumor vasculature, which have been shown to improve patient outcome when combined with standard therapy, has launched a paradigm shift on how cancer patients should be treated. It is evident that future clinical practices will focus on the incorporation of therapies that antagonize the pro-tumoral effects of such microenvironment contributors. Herein, an overview of the varying tumor-host interactions that influence tumor behaviour will be discussed, in addition to the recent efforts undertaken to target these interactions and their potential to revolutionize EOC patient care.

PMID

 22896662 [PubMed - as supplied by publisher]


Thursday, August 16, 2012

Myriad Genetics' Q4 Revenues Rise 24 Percent; Ramp up of European Operations Continues | GenomeWeb



http://www.genomeweb.com/mdx/myriad-genetics-q4-revenues-rise-24-percent-ramp-european-operations-continues


Sent from my iPhone

Women and Health Initiative: integrating needs and response : The Lancet



lltext?rss=yes


Sent from my iPhone

The Promises and Challenges of Digital Imaging as Applied to Pathology: Dr. Ulysses G.J. Balis



http://www.youtube.com/watch?v=j1yh-Oak528&feature=youtube_gdata_player


Sent from my iPhone

Myriad wins gene patent ruling from US appeals court




Myriad wins gene patent ruling from US appeals court

(Reuters) - A U.S. federal appeals court has once again affirmed the right of Myriad Genetics Inc to patent two genes linked to breast and ovarian cancer, after the U.S. Supreme Court told it to take another look at the hotly contested case.




Sent from my iPhone

Mixed Endocervical Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Cervix With Ovarian Metastasis of the Former Component: A Report of 2 Cases




Mixed Endocervical Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Cervix With Ovarian Metastasis of the Former Component: A Report of 2 Cases

imageEndocervical adenocarcinomas (ECAs) uncommonly metastasize to the ovary; however, when they do they sometimes closely mimic a mucinous/endometrioid ovarian primary tumor. Here, 2 cases of mixed moderately differentiated ECA and high-grade cervical neuroendocrine carcinoma in which the ECA component metastasized to the ovary have been delineated and reported. In both cases, the primary tumor and the metastatic tumor were diffusely positive for p16 and high-risk human papillomavirus. Although similar to previously reported cases of adenocarcinoma in situ and invasive ECAs with ovarian involvement, none of the cases reported to date had concurrent neuroendocrine carcinoma with metastasis of the lower-grade component. In this respect, our cases are unique. The presence of lower uterine segment involvement in both cases and high-risk human papillomavirus positivity in the primary and metastatic tumors suggest a metastatic process, perhaps through transtubal spread, rather than independent primaries.

Chemo Resistance in Ovarian Cancer Has Genetic Basis - Cancer Network



cernetwork.com/ovarian-cancer/content/article/10165/2097235


Sent from my iPhone

Appeals Court Affirms Isolated DNA Patents in Myriad Case | GenomeWeb



http://www.genomeweb.com/mdx/appeals-court-affirms-isolated-dna-patents-myriad-case


Sent from my iPhone

Colon and Rectal Cancer: The Myth of 2 Beasts (mobile format)



http://www.medscape.com/viewarticle/768556?src=rss

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.




Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Related Articles

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.


Cancer Treat Rev. 2012 Oct;38(6):767-75


Authors: Diaz-Padilla I, Duran I, Clarke BA, Oza AM


Abstract

Advanced recurrent gynecological malignancies have a poor prognosis despite systemic treatment, which is usually cytotoxic chemotherapy. Responses are generally short-lived and more effective treatments are needed. Rationally designed molecularly targeted therapy is an emerging and important option in this setting. The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase of the phosphatidylinositol-3-kinase (PI3K)/AKT signaling pathway with a critical role in controlling cancer cellular growth, metabolism and cell cycle progression. Aberrant PI3K-dependent signaling occurs frequently in a wide range of tumor types, including ovarian, endometrial and cervical cancer. Early clinical studies of first-generation mTOR inhibitors have shown promising clinical activity in endometrial cancer. However, the molecular basis of sensitivity and resistance to these agents remains largely unknown. In this review, we will update the clinical and biological data underlying the development of first generation mTOR inhibitors in the treatment of gynecological tumors. The role of potential new combination regimens with mTOR inhibitors in gynecological cancers will also be discussed.

PMID: 22381585 [PubMed - indexed for MEDLINE]



Sent from my iPhone

Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC).




Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC).


Genetics, Inheritance and Strategies for Prevention in Populations at High Risk of Colorectal Cancer (CRC).


Recent Results Cancer Res. 2012;191:157-83


Authors: Burn J, Mathers J, Bishop DT


Abstract

Hereditary forms of colorectal cancer account for less than 5 % of colorectal cancer but attract disproportionate attention because they offer an opportunity for effective surgical prophylaxis, influence the health of the wider family and give insight into the critical pathways of carcinogenesis. Familial Adenomatous Polyposis (FAP) due to loss of the APC gene and Lynch syndrome or Hereditary Non-Polyposis Colon Cancer (HNPCC) due to breakdown in MisMatch Repair are the principal syndromes of broader interest and both have been the subject of chemoprevention trials. There has been a longstanding interest in non-steroidal anti inflammatories in FAP where trials have shown regression of polyps with the "pro drug"sulindac and the selective COX2 inhibitors though impact on long-term cancer risk is not confirmed. The CAPP1 trial focused on two interventions in a factorial design, aspirin and resistant starch or fermentable fibre. Resistant starch is not absorbed in the small intestine and undergoes colonic fermentation to short-chain fatty acids including butyrate which have anti-cancer effects. Polyposis registry clinicians across Europe recruited adolescents with FAP to receive aspirin (600 mg as 2 tablets/d) and/or 30 g as 2 sachets/d in a 1:1 blend of potato starch and high amylose maize starch [Hylon VII]) with placebo control for at least a year or until surgery before age 21. Fifty-nine percent (133/227) of recruits had a baseline and at least one other endoscopy. After a median of 17 months , the primary endpoint of a risk of an increased polyp number in the rectum and sigmoid colon was not significantly reduced in either treatment group with relative risks of 0.77 (aspirin; 95 % CI, 0.54-1.10;) and 1.05 (RS; 95 % CI, 0.73-1.49. The diameter of the largest polyp detected tended to be smaller in the aspirin arm. The planned subgroup analyses of patients who elected to continue on study for more than one year found a significant reduction in the size of the largest polyp in the aspirin versus non-aspirin group (p = 0.02), Mean crypt length decreased significantly over time on study in the two combined RS groups, compared with the two combined non-RS groups (p < 0.0001 for interaction), in a model of the interaction between intervention and time. In CAPP2, 1009 Lynch syndrome gene carriers were recruited from 43 international centres. 937 commenced intervention: 600mg enteric coated aspirin and/or 30grams of the resistant starch Novelose in a 2 by 2 factorial placebo controlled design. After a mean of 29 months, intervention, there was no evidence that either agent influenced ...



Sent from my iPhone